The stock of Capricor Therapeutics Inc (CAPR) has gone down by -43.51% for the week, with a -28.72% drop in the past month and a -52.45% drop in the past quarter. The volatility ratio for the week is 20.19%, and the volatility levels for the past 30 days are 11.29% for CAPR. The simple moving average for the last 20 days is -37.82% for CAPR’s stock, with a simple moving average of -46.07% for the last 200 days.
Is It Worth Investing in Capricor Therapeutics Inc (NASDAQ: CAPR) Right Now?
CAPR has 36-month beta value of 0.95. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CAPR is 40.12M, and currently, short sellers hold a 26.60% ratio of that float. The average trading volume of CAPR on May 09, 2025 was 1.70M shares.
CAPR) stock’s latest price update
The stock price of Capricor Therapeutics Inc (NASDAQ: CAPR) has dropped by -3.87 compared to previous close of 6.97. Despite this, the company has seen a fall of -43.51% in its stock price over the last five trading days. accessnewswire.com reported 2025-05-09 that NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Capricor Therapeutics, Inc. (“Capricor Therapeutics, Inc.”) (NASDAQ:CAPR) concerning possible violations of federal securities laws. Capricor issued a press release on May 5, 2025, announcing that after “the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company’s Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy”, the FDA had “confirmed its intent to hold an advisory committee meeting” in connection with the BLA.
Analysts’ Opinion of CAPR
Many brokerage firms have already submitted their reports for CAPR stocks, with Piper Sandler repeating the rating for CAPR by listing it as a “Overweight.” The predicted price for CAPR in the upcoming period, according to Piper Sandler is $35 based on the research report published on October 21, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CAPR reach a price target of $14. The rating they have provided for CAPR stocks is “Outperform” according to the report published on May 17th, 2024.
Cantor Fitzgerald gave a rating of “Overweight” to CAPR, setting the target price at $8 in the report published on January 05th of the previous year.
CAPR Trading at -41.40% from the 50-Day Moving Average
After a stumble in the market that brought CAPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.37% of loss for the given period.
Volatility was left at 11.29%, however, over the last 30 days, the volatility rate increased by 20.19%, as shares sank -24.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -53.65% lower at present.
During the last 5 trading sessions, CAPR fell by -43.80%, which changed the moving average for the period of 200-days by +39.44% in comparison to the 20-day moving average, which settled at $10.77. In addition, Capricor Therapeutics Inc saw -51.45% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CAPR starting from Nippon Shinyaku Co Ltd, who purchase 2,798,507 shares at the price of $5.36 back on Sep 20 ’24. After this action, Nippon Shinyaku Co Ltd now owns 7,090,351 shares of Capricor Therapeutics Inc, valued at $14,999,998 using the latest closing price.
Stock Fundamentals for CAPR
Current profitability levels for the company are sitting at:
- -1.91 for the present operating margin
- 0.95 for the gross margin
The net margin for Capricor Therapeutics Inc stands at -1.82. The total capital return value is set at -0.28. Equity return is now at value -48.16, with -35.31 for asset returns.
Based on Capricor Therapeutics Inc (CAPR), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -27.56.
Currently, EBITDA for the company is -41.17 million with net debt to EBITDA at 0.24. When we switch over and look at the enterprise to sales, we see a ratio of 13.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.77.
Conclusion
To put it simply, Capricor Therapeutics Inc (CAPR) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
